Clinical Trial Update: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations [Phase 2]

View source ↗

Summary

Phase II open-label randomized study comparing AUY922 against pemetrexed or docetaxel in NSCLC patients with EGFR mutations; trial terminated with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AUY922 (luminespib)
• DOCETAXEL (DOCETAXEL)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: TERMINATED | Results posted: 2017-03-13